glp-1

WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services. • Eli Lilly...

Hims & Hers Health reported first-quarter financial results Monday after market close. • Hims & Hers Health shares are retreating from recent levels. Why is HIMS stock dropping? Here are the key highlights. Hims & Hers Q1 Financials Hims & Hers reported first-quarter...

Eli Lilly and Co. (NYSE:LLY) revealed plans to inject an extra $4.5 billion into two of its Indiana manufacturing sites on Wednesday. This move escalates its total capital expansion in the state since 2020 to over $21 billion. The additional funding is intended to support the production of...

Big pharma is currently facing a potential “bubble effect” due to the surging demand for weight loss and diabetes drugs, as revealed in a report by Deloitte released on Monday. Drugs such as Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly’s (NYSE:LLY...

Novo Nordisk A/S (NYSE:NVO) has lost more than half its value from its peak. NVO stock is down 58% over the past year and more than 40% in just the past month, collapsing from a 52-week high of $91.90 to near $38. But beneath the selloff, something unusual has emerged. Novo Nordisk is no longer...

Novo Nordisk AS (NYSE:NVO), once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what analysts are calling a “worst-case scenario.”  NVO stock is tumbling. See the chart and price action here.  Shares of Novo Nordisk stock plunged over 16% in...

Telehealth giant Hims & Hers Health, Inc. (NYSE:HIMS) may have flown too close to the sun and is now under fire on multiple fronts, including federal intervention, criminal investigation and a patent war. Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much...

Novo Nordisk A/S' (NYSE:NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge. For context, Eli Lilly And Co's (NYSE:LLY) Zepbound hit about...

Linda Yaccarino may have a resume that many people around the world envy. In the past two years, Yaccarino has worked for Elon Musk and is now Tom Brady's boss. • Novo Nordisk stock is facing resistance. Why is NVO stock trading lower? Tom Brady Joins Telehealth Startup eMed In 23 seasons in...

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Track LLY stock here. GLP-1 Demand Is Becoming Structural The obesity and...

Novo Nordisk A/S (NYSE:NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot that could flip 2026 from bruised to breakout. Yet here we are: a 69% reset, sentiment in shambles, and a business that looks nothing like...

Novo Nordisk A/S (NASDAQ:NVO) is back in the headlines, and not just for its blockbuster weight-loss drug, Ozempic. President Donald Trump recently suggested a dramatic price cut for the drug, sparking some short-term market jitters. But underneath the noise, the stock is cheap at a 14 P/E, and its...

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that...

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook. Obesity & Heart...

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1...